These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 29043891)

  • 1. Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis.
    Nandy A; Gaïni S; Sore P
    Scand J Rheumatol; 2018 Jul; 47(4):334-335. PubMed ID: 29043891
    [No Abstract]   [Full Text] [Related]  

  • 2. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
    Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Ro 52 positive dermatomyositis presenting as rapidly progressive interstitial lung disease.
    Conway R; O'Donnell R; Fahy R; Doran MF; Cunnane G; O'Shea FD
    QJM; 2014 Jul; 107(7):593-4. PubMed ID: 24336848
    [No Abstract]   [Full Text] [Related]  

  • 4. Three cases of autoimmune-associated haemophagocytic syndrome in dermatomyositis with anti-MDA5 autoantibody.
    Honda M; Moriyama M; Kondo M; Kumakura S; Sumita Y; Murakawa Y
    Scand J Rheumatol; 2020 May; 49(3):244-246. PubMed ID: 31571515
    [No Abstract]   [Full Text] [Related]  

  • 5. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
    Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.
    Endo Y; Koga T; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Hosono Y; Mimori T; Kawakami A
    Medicine (Baltimore); 2018 Jun; 97(26):e11024. PubMed ID: 29952940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
    Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
    Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis.
    Zhang X; Zhou S; Wu C; Li M; Wang Q; Zhao Y; Zeng X
    Rheumatology (Oxford); 2021 Jul; 60(7):e227-e228. PubMed ID: 33410494
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis.
    Hisanaga J; Kotani T; Fujiki Y; Yoshida S; Takeuchi T; Makino S
    Int J Rheum Dis; 2017 Dec; 20(12):2182-2185. PubMed ID: 28752606
    [No Abstract]   [Full Text] [Related]  

  • 10. Spontaneous pneumomediastinum in a dermatomyositis patient with anti-melanoma differentiation-associated gene-5 antibody and interstitial lung disease despite an initial response to immunosuppressant.
    Chan CWS; Chung HY; Lau CS; Tsang HHL
    Int J Rheum Dis; 2019 Mar; 22(3):521-524. PubMed ID: 28580698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
    Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
    Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis.
    So H; Wong VTL; Lao VWN; Pang HT; Yip RML
    Clin Rheumatol; 2018 Jul; 37(7):1983-1989. PubMed ID: 29713969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
    Gil B; Merav L; Pnina L; Chagai G
    Clin Rheumatol; 2016 Aug; 35(8):2125-2130. PubMed ID: 25846833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
    Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.
    Osawa T; Morimoto K; Sasaki Y; Matsuda S; Yamana K; Yano R; Uchiyama T; Goto H
    Intern Med; 2018 Feb; 57(3):387-391. PubMed ID: 29093381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan.
    Tokunaga K; Hagino N
    Intern Med; 2017; 56(11):1399-1403. PubMed ID: 28566605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vocal cord palsy in refractory anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis.
    Alsaed OS; Alamlih LI; Farfar KA; Mohd TRN; Alemadi SAAR; Malallah HA
    Rheumatology (Oxford); 2020 Oct; 59(10):e66-e67. PubMed ID: 32252065
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
    Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatoid Arthritis Complicated with Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Interstitial Pneumonia.
    Matsumoto H; Sato S; Fujita Y; Yashiro-Furuya M; Matsuoka N; Asano T; Kobayashi H; Watanabe H; Migita K
    Intern Med; 2019 Mar; 58(5):737-742. PubMed ID: 30333415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
    Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.